Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME H&N study of neoadjuvant and maintenance niraparib + dostarlimab in HPV-negative resectable head and neck squamous cell carcinoma
2024-516798-54-00Phase 2Completed
- Sponsor
- GONO Foundation
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab and niraparib in head and neck squamous cell carcinoma (HNSCC), sponsored by GONO Foundation. Primary endpoint: Major pathological response rate. Started Feb 2021; status: completed.
02
Drugs
dostarlimabniraparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-516798-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516798-54-00.